Empowering the world with transformative technologies to fight against infectious disease

Covid-19 Response

Compassionate Use

Addressing the unmet medical needs of patients with a serious or life-threatening disease or condition is important to BOA Biomedical. BOA Biomedical does maintain an Expanded Access program for circumstances where a patient with a life-threatening illness, such as COVID-19, requires treatment and the treating physician believes that the GARNET technology may be of benefit.

wyss-video-thumbnail-2-800

Our Products aspire to bring quantum leaps in innovation to the world

Detect

Rapid
detection

Recognize active infection and assess infection severity and sepsis within minutes in any setting, including the home.

Diagnose

Rapid pathogen identification

Accurately identify infection-causing pathogens, within one hour, without the need for blood cultures.

Treat

Pathogen toxin removal

Filter the toxic by-products of pathogens directly from a patient’s blood using an extracorporeal therapeutic filter.

60 Minutes Segment

Department of Defense

DIAGNOSING AND TREATING SEPSIS

BOA, DOD and their research agency, DARPA, focus research on diagnosing and treating sepsis. BOA licensed the technology from Harvard University in 2018 and was awarded emergency grants from the Department of Defense in 2020.

Press

Scroll to Top